2023 Q3 Form 10-Q Financial Statement

#000143774923023018 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $100.0K $106.8K $222.3K
YoY Change -39.77% -51.97% -70.63%
% of Gross Profit
Research & Development $30.00K $143.9K -$50.56K
YoY Change 30.89% -384.61% -806.15%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $2.510K
YoY Change -100.0% 182.02%
% of Gross Profit
Operating Expenses $134.7K $250.7K $174.2K
YoY Change -171.31% 43.87% -77.2%
Operating Profit -$174.2K
YoY Change -77.2%
Interest Expense $210.0K $120.9K -$48.78K
YoY Change -19.13% -347.89% -1591.74%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $251.6K
YoY Change -100.0%
Pretax Income $70.00K -$129.8K $28.58K
YoY Change -0.99% -554.02% -103.76%
Income Tax
% Of Pretax Income
Net Earnings $74.73K -$129.8K $28.58K
YoY Change 5.7% -554.04% -103.75%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $83.81
COMMON SHARES
Basic Shares Outstanding 355.9M 355.9M shares 317.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.140M $1.361M $2.314M
YoY Change -42.19% -41.19% 1351.97%
Cash & Equivalents $1.135M $1.361M $2.314M
Short-Term Investments
Other Short-Term Assets $20.00K $37.11K $19.92K
YoY Change 98.81% 86.3% -27.38%
Inventory
Prepaid Expenses $20.67K $37.11K $19.92K
Receivables
Other Receivables
Total Short-Term Assets $1.156M $1.398M $2.334M
YoY Change -41.69% -40.1% 1149.43%
LONG-TERM ASSETS
Property, Plant & Equipment $700.0K $704.1K $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $10.00K $10.89K $11.44K
YoY Change 2.04% -4.81% 0.0%
Other Assets
YoY Change
Total Long-Term Assets $714.6K $714.9K $715.5K
YoY Change 0.11% -0.08% -0.52%
TOTAL ASSETS
Total Short-Term Assets $1.156M $1.398M $2.334M
Total Long-Term Assets $714.6K $714.9K $715.5K
Total Assets $1.870M $2.113M $3.049M
YoY Change -30.62% -30.71% 236.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $50.00K $177.3K $187.7K
YoY Change -71.57% -5.52% -79.88%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $540.0K $864.7K $2.345M
YoY Change -70.96% -63.13% 72.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $540.0K $864.7K $2.345M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $536.5K $864.7K $2.345M
YoY Change -71.15% -63.13% 72.01%
SHAREHOLDERS EQUITY
Retained Earnings -$114.8M -$114.8M -$115.3M
YoY Change -0.36% -0.35% -0.05%
Common Stock $111.1M $111.1M $111.2M
YoY Change -0.02% -0.02% 1.03%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.264M
YoY Change 0.0%
Treasury Stock Shares 1.033M shares
Shareholders Equity $1.334M $1.248M $704.3K
YoY Change
Total Liabilities & Shareholders Equity $1.870M $2.113M $3.049M
YoY Change -30.62% -30.71% 236.56%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income $74.73K -$129.8K $28.58K
YoY Change 5.7% -554.04% -103.75%
Depreciation, Depletion And Amortization $0.00 $0.00 $2.510K
YoY Change -100.0% 182.02%
Cash From Operating Activities -$230.0K -$184.3K -$459.3K
YoY Change -32.77% -59.87% 422.04%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 2.726M
YoY Change -100.0% -92835.37%
NET CHANGE
Cash From Operating Activities -230.0K -184.3K -459.3K
Cash From Investing Activities
Cash From Financing Activities 0.000 0.000 2.726M
Net Change In Cash -230.0K -184.3K 2.267M
YoY Change -32.77% -108.13% -2593.54%
FREE CASH FLOW
Cash From Operating Activities -$230.0K -$184.3K -$459.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001408146
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2023Q2 scy Common Stock Votes Per Share
CommonStockVotesPerShare
1 pure
scy Accruals To Related Parties Reversed
AccrualsToRelatedPartiesReversed
0 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 usd
CY2022Q4 us-gaap Cash
Cash
1852710 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
33541 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1866251 usd
CY2022Q4 us-gaap Regulatory Assets Noncurrent
RegulatoryAssetsNoncurrent
10699 usd
CY2022Q4 us-gaap Assets
Assets
2601003 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2513 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2932 usd
CY2023Q2 us-gaap Legal Fees
LegalFees
0 usd
CY2022Q2 us-gaap Legal Fees
LegalFees
0 usd
us-gaap Legal Fees
LegalFees
0 usd
us-gaap Legal Fees
LegalFees
17000 usd
CY2023Q2 scy Exploration Expense Recovery
ExplorationExpenseRecovery
143902 usd
CY2022Q2 scy Exploration Expense Recovery
ExplorationExpenseRecovery
-50557 usd
scy Exploration Expense Recovery
ExplorationExpenseRecovery
181126 usd
scy Exploration Expense Recovery
ExplorationExpenseRecovery
-31370 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16536 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50815 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
46287 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
131111 usd
CY2023Q2 us-gaap General Insurance Expense
GeneralInsuranceExpense
7850 usd
CY2022Q2 us-gaap General Insurance Expense
GeneralInsuranceExpense
7578 usd
us-gaap General Insurance Expense
GeneralInsuranceExpense
15682 usd
us-gaap General Insurance Expense
GeneralInsuranceExpense
15487 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
19217 usd
CY2022Q2 us-gaap Professional Fees
ProfessionalFees
28538 usd
us-gaap Professional Fees
ProfessionalFees
52395 usd
us-gaap Professional Fees
ProfessionalFees
63322 usd
CY2023Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
63166 usd
CY2022Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
135351 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
131289 usd
CY2023Q2 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
0 usd
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
0 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
174238 usd
us-gaap Operating Expenses
OperatingExpenses
430516 usd
us-gaap Operating Expenses
OperatingExpenses
425056 usd
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9256 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4957 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-30596 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1723 usd
CY2023Q2 scy Accruals Reversal
AccrualsReversal
0 usd
CY2022Q2 scy Accruals Reversal
AccrualsReversal
251600 usd
scy Accruals Reversal
AccrualsReversal
0 usd
scy Accruals Reversal
AccrualsReversal
1032044 usd
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
10353 usd
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
0 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
17732 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
0 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
119818 usd
CY2022Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-53741 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
549624 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-53741 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
355860813
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
341020614
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
355860813
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
348399718
us-gaap Net Income Loss
NetIncomeLoss
106244 usd
us-gaap Net Income Loss
NetIncomeLoss
551524 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
0 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
2932 usd
us-gaap Share Based Compensation
ShareBasedCompensation
48633 usd
us-gaap Share Based Compensation
ShareBasedCompensation
88447 usd
scy Accruals Reversal
AccrualsReversal
-0 usd
scy Accruals Reversal
AccrualsReversal
1032044 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
549624 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-53741 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-41957 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
842 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3567 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-15127 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-135539 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-185190 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-491896 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-506305 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2647852 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
-0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
28418 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
106990 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2726423 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-491896 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2220118 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1852710 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
93894 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1360814 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2314012 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-880349 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
522946 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-357403 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
88447 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
106989 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2619434 usd
CY2022Q2 scy Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
1781779 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
28578 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
704266 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
61222 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
70701 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
836189 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
48611 usd
CY2022Q4 scy Share Issuance Costs
ShareIssuanceCosts
19892 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
228371 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1093279 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26949 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
236000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1356228 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21684 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-129756 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1248156 usd
us-gaap Nature Of Operations
NatureOfOperations
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>1.</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NATURE AND CONTINUANCE OF OPERATIONS</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">Scandium International Mining Corp. (the “Company”) is a specialty metals and alloys company focusing on scandium and other specialty metals.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">The Company was incorporated under the laws of the Province of British Columbia, Canada in 2006. The Company currently trades on the Toronto Stock Exchange (TSX) under the symbol “SCY”.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company’s focus is on the exploration and evaluation of its specialty metals assets, specifically the Nyngan scandium deposit located in New South Wales, Australia, The Company is an exploration stage company and anticipates incurring significant additional expenditures prior to production and any and all of its properties.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">These condensed interim consolidated financial statements have been prepared on a going concern basis that contemplates the realization of assets and discharge of liabilities at their carrying values in the normal course of business for the foreseeable future. These financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company currently earns no operating revenues and will require additional capital in order to advance the Nyngan property. The Company’s ability to continue as a going concern is uncertain and is dependent upon the generation of profits from mineral properties, obtaining additional financing and maintaining continued support from its shareholders and creditors. These are material uncertainties that raise substantial doubt about the Company’s ability to continue as a going concern. In the event that additional financial support is not received, or operating profits are not generated, the carrying values of the Company’s assets may be adversely affected.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">The outbreak of COVID-19 and political upheavals in various countries have caused significant volatility in commodity prices. While these effects are expected to be temporary, the duration of the business disruptions internationally and related financial impact cannot be reasonably estimated at this time.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;"><b>Use of estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">The preparation of unaudited condensed interim consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuations, asset impairment, stock-based compensation, derivative liabilities and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between estimates and the actual results, future results of operations will be affected.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company considers itself to be an exploration stage company and will consider the transition to development stage after it receives funding to begin mine construction, and board approval.</p>
us-gaap Short Term Lease Cost
ShortTermLeaseCost
15669 usd
CY2023Q2 us-gaap Mineral Properties Gross
MineralPropertiesGross
704053 usd
scy Accruals To Related Parties Reversed
AccrualsToRelatedPartiesReversed
669733 usd
CY2023Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
900000
CY2022Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
900000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
106989 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
135000 cad
CY2022Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.15
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
549624 usd
scy Unrealized Foreign Currency Transaction Gain Losses Unrealized
UnrealizedForeignCurrencyTransactionGainLossesUnrealized
42149 usd
CY2023Q2 scy Derivativewarrants
Derivativewarrants
687410 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
34615000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.18
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
5700000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.09
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
900000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.15
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3535000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.37
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
34665000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
5700000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.23
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
28965000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.12
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
27540000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.12
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
28965000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
27540000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
48633 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
88447 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5700000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.06
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1033333
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1264194 usd
CY2023Q2 us-gaap Mineral Rights
MineralRights
704053 usd
CY2023Q2 scy Property Plant And Equipment Net Including Mineral Rights Total
PropertyPlantAndEquipmentNetIncludingMineralRightsTotal
704053 usd
CY2022Q4 us-gaap Mineral Rights
MineralRights
704053 usd
CY2022Q4 scy Property Plant And Equipment Net Including Mineral Rights Total
PropertyPlantAndEquipmentNetIncludingMineralRightsTotal
704053 usd
scy Accruals To Related Parties Reversed
AccrualsToRelatedPartiesReversed
669733 usd
scy Accruals To Former Contractors And Consultants Reversed
AccrualsToFormerContractorsAndConsultantsReversed
362311 usd

Files In Submission

Name View Source Status
0001437749-23-023018-index-headers.html Edgar Link pending
0001437749-23-023018-index.html Edgar Link pending
0001437749-23-023018.txt Edgar Link pending
0001437749-23-023018-xbrl.zip Edgar Link pending
a01.jpg Edgar Link pending
a02.jpg Edgar Link pending
ex_558288.htm Edgar Link pending
ex_558289.htm Edgar Link pending
ex_558290.htm Edgar Link pending
ex_558291.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
logo.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
scy-20230630.xsd Edgar Link pending
scy20230630_10q.htm Edgar Link pending
scy20230630_10qimg002.jpg Edgar Link pending
scy20230630_10qimg003.jpg Edgar Link pending
scy-20230630_cal.xml Edgar Link unprocessable
scy-20230630_def.xml Edgar Link unprocessable
scy-20230630_lab.xml Edgar Link unprocessable
scy-20230630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending
scy20230630_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable